VANTAS delivers more freedom
and flexibility in 4 key ways:

Chart your patients’ course for more freedom with once-yearly
treatment flexibility

LHRH therapy that frees you and your patients from a schedule of multiple injections

Increased flexibility for you—

Multiple office efficiencies¹ and scheduling benefits, including:

Freedom to create a flexible plan for your patients’ overall treatment

Decreased staff time spent on re-booking cancelled appointments, billing, paperwork and patient co-payments

Freedom from ongoing need to track and replenish injection stock

Exam rooms free for other procedures

Increased flexibility for your patients—

Multiple therapeutic and scheduling benefits, including:

A full year of continuous LHRH therapy coverage

Office visits at times they choose with you—not at times determined by injection schedules

More time to spend their way

Freedom to chart a course of treatment that accommodates their lifestyle—
and your priorities

Reference: 1. Scionti SM. Practice management and patient care: is there an ideal situation for both patients and physician practices in light of legislative reform? Urology. 2004;64(suppl 5A):8-14.

Important Safety Information

VANTAS is contraindicated in women, pediatric patients and patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the other components of VANTAS.

VANTAS, like other LHRH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, cases of ureteral obstruction and spinal cord compression. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

Implant insertion and removal is a surgical procedure and should use aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. In all clinical trials combined, an implant was not recovered in 8 patients, 2 of these 8 patients had serum testosterone levels above castrate level and the implant was not visualized with ultrasound. In all of the 8 patients, the implant was not palpable.

Response to VANTAS should be monitored measuring serum concentrations of testosterone and PSA periodically.

In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists.

VANTAS delivers more freedom and flexibility in 4 key ways:

Increased flexibility for you—

Increased flexibility for your patients—

Freedom to chart a course of treatment that accommodates their lifestyle— and your priorities

Click here for a larger view

Important Safety Information

VANTAS delivers more freedom
and flexibility in 4 key ways:

Freedom to chart a course of treatment that accommodates their lifestyle—
and your priorities